Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of kawasaki disease

Circulation

Volumn 125, Issue 12, 2012, Pages 1542-1550

  Lee, Youngho ^a   Schulte, Danica J ^a   Shimada, Kenichi ^a   Chen, Shuang ^a   Crother, Timothy R ^a   Chiba, Norika ^a   Fishbein, Michael C ^b   Lehman, Thomas J A ^c   Arditi, Moshe ^a  

^a BURNS AND ALLEN RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Interleukin 1 beta; Interleukin 1 receptor antagonist protein; Kawasaki disease; myocarditis; vasculitis

Indexed keywords

INFLAMMASOME; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; LACTOBACILLUS CASEI CELL WALL EXTRACT; NATURAL PRODUCT; PENTRAXIN 3; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTITIS; ARTERITIS; ARTICLE; CORONARY ARTERY; MACROPHAGE; MOUSE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ARTERITIS; CELLS, CULTURED; CORONARY VESSELS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUCOCUTANEOUS LYMPH NODE SYNDROME;

EID: 84862777294     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.072769     Document Type: Article

References (49)

1. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54:271-276.
2. Burns JC. Kawasaki disease update. Indian J Pediatr. 2009;76:71-76.
3. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA, Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease; Council on Cardiovascular Disease in the Young; American Heart Association; American Academy of Pediatrics. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110:2747-2771.
4. Burns JC, Glodé MP. Kawasaki syndrome. Lancet. 2004;364:533-544.
5. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, Kazue T, Eto G, Yamakawa R. Long-term consequences of Kawasaki disease: a 10-to 21-year follow-up study of 594 patients. Circulation. 1996;94: 1379-1385.
6. Burns JC, Shike H, Gordon JB, Malhotra A, Schoenwetter M, Kawasaki T. Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol. 1996;28:253-257.
7. Gordon JB, Kahn AM, Burns JC. When children with Kawasaki disease grow up: myocardial and vascular complications in adulthood. J Am Coll Cardiol. 2009;54:1911-1920.
8. Fukazawa R. Long-term prognosis of Kawasaki disease: increased cardiovascular risk? Curr Opin Pediatr. 2010;22:587-592.
9. Senzaki H. Long-term outcomes of Kawasaki disease. Circulation. 2008; 118:2763-2772.
10. Rowley AH, Baker SC, Orenstein JM, Shulman ST. Searching for the cause of Kawasaki disease: cytoplasmic inclusion bodies provide new insight. Nat Rev Microbiol. 2008;6:394-401.
11. Rowley AH, Baker SC, Shulman ST, Garcia FL, Fox LM, Kos IM, Crawford SE, Russo PA, Hammadeh R, Takahashi K, Orenstein JM. RNA-containing cytoplasmic inclusion bodies in ciliated bronchial epithelium months to years after acute Kawasaki disease. PLoS One. 2008; 3:e1582.
12. Rowley AH, Shulman ST, Garcia FL, Guzman-Cottrill JA, Miura M, Lee HL, Baker SC. Cloning the arterial IgA antibody response during acute Kawasaki disease. J Immunol. 2005;175:8386-8391.
13. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, Colan SD, Duffy CE, Fulton DR, Glode MP, Mason WH, Meissner HC, Rowley AH, Shulman ST, Reddy V, Sundel RP, Wiggins JW, Colton T, Melish ME, Rosen FS. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633-1639.
14. Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW. Gamma globulin re-treatment in Kawasaki disease. J Pediatr. 1993;123:657-659.
15. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease: US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J. 1998;17:1144-1148.
16. Tremoulet A, Best B, Song S, Wang S, Corinaldesi E, Eichenfield J, Martin D, Newburger J, Burns J. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr. 2008;153: 117-121.
17. Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, Baker A, Fulton DR, Sundel RP, Newburger JW. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr. 2011;158:644.e1-649.e1.
18. Lehman T, Walker S, Mahnovski V, McCurdy D. Coronary arteritis in mice following the systemic injection of group B Lactobacillus casei cell walls in aqueous suspension. Arthritis Rheum. 1985;28:652-659.
19. Lehman TJA, Sherry B, Gietl DM, Nguyen HT, Cerami A. Suppression of Lactobacillus casei cell wall induced coronary arteritis in mice by antibody to murine tumor necrosis factor. In: Proceedings of the Third International Conference on Kawasaki Disease. 1988:203-206.
20. Yilmaz A, Rowley A, Schulte DJ, Doherty TM, Schroder NW, Fishbein MC, Kalelkar M, Cicha I, Schubert K, Daniel WG, Garlichs CD, Arditi M. Activated myeloid dendritic cells accumulate and co-localize with CD3T cells in coronary artery lesions in patients with Kawasaki disease. Exp Mol Pathol. 2007;83:93-103.
21. Myones BL, Bathoria JM, Lehman TJA, Shulman ST. Human IVIG inhibits Lactobacillus casei-inducible coronary arteritis in a murine model. In: Kato H, ed. Kawasaki Disease: Proceedings of the V International Kawasaki Disease Symposium, Fukuoka, Japan. Amsterdam: Elsevier Science; 1995:252-256.
22. Thornberry N, Bull H, Calaycay J, Chapman K, Howard A, Kostura M, Miller D, Molineaux S, Weidner J, Aunins J. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992;356:768-774.
23. Bujak M, Frangogiannis N. The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp (Warsz). 2009;57:165-176.
24. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol. 2009;36:1118-1125.
25. Mitroulis I, Skendros P, Ritis K. Targeting IL-1beta in disease: the expanding role of NLRP3 inflammasome. Eur J Intern Med. 2010;21: 157-163.
26. Weng K, Hsieh K, Ho T, Huang S, Lai C, Chiu Y, Huang S, Lin C, Hwang Y, Ger L. IL-1b polymorphism in association with initial intravenous immunoglobulin treatment failure in Taiwanese children with Kawasaki disease. Circ J. 2010;74:544-551.
27. Maury C, Salo E, Pelkonen P. Circulating interleukin-1 beta in patients with Kawasaki disease. N Engl J Med. 1988;319:1670-1671.
28. Popper S, Shimizu C, Shike H, Kanegaye J, Newburger J, Sundel R, Brown P, Burns J, Relman D. Gene-expression patterns reveal underlying biological processes in Kawasaki disease. Genome Biol. 2007;8:R261.
29. Fury W, Tremoulet A, Watson V, Best B, Shimizu C, Hamilton J, Kanegaye J, Wei Y, Kao C, Mellis S, Lin C, Burns J. Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance. Hum Immunol. 2010;71:865-873.
30. Leung DY, Cotran RS, Kurt-Jones E, Burns JC, Newburger JW, Pober JS. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet. 1989;2:1298-1302.
31. Suzuki H, Uemura S, Tone S, Iizuka T, Koike M, Hirayama K, Maeda J. Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-alpha and interleukin-1 beta by peripheral blood monocytes in the acute phase of Kawasaki disease. Eur J Pediatr. 1996; 155:291-296.
32. Arend WP, Leung DY. IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev. 1994;139:71-78.
33. Okitsu-Negishi S, Furusawa S, Kawa Y, Hashira S, Ito S, Hiruma F, Mizoguchi M, Yoshino K, Abe T. Suppressive effect of intravenous immunoglobulins on the activity of interleukin-1. Immunol Res. 1994;13: 49-55.
34. Rosenkranz M, Schulte D, Agle L, Wong M, Zhang W, Ivashkiv L, Doherty T, Fishbein M, Lehman T, Michelsen K, Arditi M. TLR2 and MYD88 contribute to Lactobacillus casei extract-induced focal coronary arteritis in a mouse model of Kawasaki disease. Circulation. 2005;112: 2966-2973.
35. Lee T, Furukawa S, Fukuda Y, Yabuta K, Kato H. Plasma prostaglandin E2 level in Kawasaki disease. Prostaglandins Leukot Essent Fatty Acids. 1988;31:53-57.
36. Schulte DJ, Yilmaz A, Shimada K, Fishbein MC, Lowe EL, Chen S, Wong M, Doherty TM, Lehman T, Crother TR, Sorrentino R, Arditi M. Involvement of innate and adaptive immunity in a murine model of coronary arteritis mimicking Kawasaki disease. J Immunol. 2009;183: 5311-5318.
37. Chan W, Duong T, Yeung R. Presence of IFN-gamma does not indicate its necessity for induction of coronary arteritis in an animal model of Kawasaki disease. J Immunol. 2004;173:3492-3503.
38. Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, Ma L, Watowich SS, Jetten AM, Tian Q, Dong C. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity. 2009;30: 576-587.
39. Lasigliè D, Traggiai E, Federici S, Alessio M, Buoncompagni A, Accogli A, Chiesa S, Penco F, Martini A, Gattorno M. Role of IL-1 beta in the development of human T(h) 17 cells: lesson from NLPR3 mutated patients. PLoS One. 2011;6:e20014.
40. Lehman TJ. Can we prevent long term cardiac damage in Kawasaki disease? Lessons from Lactobacillus casei cell wall-induced arteritis in mice. Clin Exp Rheumatol. 1993;11(suppl 9):S3-S6.
41. Lehman TJ, Mahnovski V. Animal models of vasculitis: lessons we can learn to improve our understanding of Kawasaki disease. Rheum Dis Clin North Am. 1988;14:479-487.
42. Hui-Yuen J, Duong T, Yeung R. TNF-alpha is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J Immunol. 2006;176:6294-6301.
43. Deban L, Jaillon S, Garlanda C, Bottazzi B, Mantovani A. Pentraxins in innate immunity: lessons from PTX3. Cell Tissue Res. 2010;343: 237-249.
44. Norata G, Garlanda C, Catapano A. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med. 2010;20:35-40.
45. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315:341-347.
46. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics. 2000; 105:E78.
47. Son MB, Gauvreau K, Ma L, Baker AL, Sundel RP, Fulton DR, Newburger JW. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics. 2009;124:1-8.
48. Shulman ST. Is there a role for corticosteroids in Kawasaki disease? J Pediatr. 2003;142:601-603.
49. Oishi T, Fujieda M, Shiraishi T, Ono M, Inoue K, Takahashi A, Ogura H, Wakiguchi H. Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm. Circ J. 2008;72:850-852.